ReNeuron encouraged by progress in stroke and RP treatments

0
49
  • Proactive news headlines: ReNeuron, Live Company, Coro Energy….
  • ReNeuron Group completes first dosing of patients in study for new degenerative eye disease therapy
dna strand

Quick facts: ReNeuron Group PLC

Follow

View company profile

ReNeuron Group PLC is a leading, clinical-stage stem cell business.

The company’s primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

01 Oct 2021

(, ) said it had restarted in all geographies recruitment to its phase IIa human retinal progenitor (hRPC) cell therapy trial treating patients with degenerative eye disease retinitis pigmentosa.

() will bring a taste of the Antarctic throughout the centre of Hampshire town Eastleigh next month, as part of a new contract for its BRICKLIVE ‘March of the Penguins’ display.

(, , , ). announced it has completed the acquisition of Big Swig, Inc., a US-based seller of sparkling water beverages.

(, ) has extended the exclusivity period agreed with the company’s Vietnamese rooftop solar project partner, Vinh Phuc Electrical Mechanical Installation until the end of October 2021. Current in-country COVID-19 restrictions include limitations on being able to formally lodge papers with the Vietnamese government.

Read more

01 Oct 2021

(, ) said it received regulatory approval to restart recruitment in all geographies for its phase IIa human retinal progenitor (hRPC) cell therapy trial, treating patients with degenerative eye disease retinitis pigmentosa.

With the remaining people in the study expected to be treated by the end of the year, researchers are slated to present early efficacy data from the expansion cohort in the first quarter of 2022.

Read more

06 Aug 2021

(, ) has announced Catherine Isted will be joining the board as Chief Financial Officer effective 11 October, 2021.

Isted, who holds a first-class chemistry degree and is also a chartered accountant, is joining from Oxford Biomedica PLC, where she is currently part of the finance leadership team heading up the corporate development and investor relations functions.

Read more

19 Jan 2021

‘s () Michael Hunt talks to Proactive London following news on their data from their latest clinical assessment, which will be presented later this year.

Hunt talks through the phase IIa extension study of its human retinal progenitor cell therapy for degenerative eye disease.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

FTSE dives on worries over the UK economy, gas prices, furlough ending and…

FTSE 100 endured a tough start to the day dropping more than 1% on worries over the UK economy, gas prices, furlough ending and China’s need for energy. London’s blue-chip index was down 56 to 7,029 in early trades.

JD Wetherspoon (LSE:JDW) (LSE:JDW) PLC said it is “cautiously optimistic”…

1 day, 1 hour ago

3 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here